Recent from talks
Medetomidine
Knowledge base stats:
Talk channels stats:
Members stats:
Medetomidine
Medetomidine is a veterinary anesthetic medication with potent sedative effects and emerging illicit drug adulterant.
It is a racemic mixture of two stereoisomers, levomedetomidine and dexmedetomidine, the latter being the isomer with the pharmacologic effect as an alpha 2- adrenergic agonist. Effects can be reversed using atipamezole.
It was developed by Orion Pharma. It is approved for dogs in the United States, and distributed in the United States by Pfizer Animal Health and by Novartis Animal Health in Canada under the product name Domitor. Starting in 2022 medetomidine has been detected in the US in samples of illicit drugs and associated with overdoses.
The free base form of medetomidine is sold as an antifouling substance for marine paints.
Medetomidine was developed by Orion Pharma and launched in 2007.
Medetomidine is a racemic mixture of two optical or stereoisomers, levomedetomidine and dexmedetomidine. The latter causes the alpha 2- adrenergic agonist effects.
Medetomidine is an α2-adrenergic receptor agonist that binds at a ratio of 1620:1 with imidazoline receptor activity.
Medetomidine is metabolised in the liver via hydroxylation.
Hub AI
Medetomidine AI simulator
(@Medetomidine_simulator)
Medetomidine
Medetomidine is a veterinary anesthetic medication with potent sedative effects and emerging illicit drug adulterant.
It is a racemic mixture of two stereoisomers, levomedetomidine and dexmedetomidine, the latter being the isomer with the pharmacologic effect as an alpha 2- adrenergic agonist. Effects can be reversed using atipamezole.
It was developed by Orion Pharma. It is approved for dogs in the United States, and distributed in the United States by Pfizer Animal Health and by Novartis Animal Health in Canada under the product name Domitor. Starting in 2022 medetomidine has been detected in the US in samples of illicit drugs and associated with overdoses.
The free base form of medetomidine is sold as an antifouling substance for marine paints.
Medetomidine was developed by Orion Pharma and launched in 2007.
Medetomidine is a racemic mixture of two optical or stereoisomers, levomedetomidine and dexmedetomidine. The latter causes the alpha 2- adrenergic agonist effects.
Medetomidine is an α2-adrenergic receptor agonist that binds at a ratio of 1620:1 with imidazoline receptor activity.
Medetomidine is metabolised in the liver via hydroxylation.
Recent media